Coalition of advocates to vaccinate of Western European citizens aged 60 years and older by Michel, Jean-Pierre et al.
Aging Clin Exp Res, Vol. 21, No. 3 254
Key words: Healthy aging, public health, vaccine.
Correspondence: Jean-Pierre Michel, MD, Department of Rehabilitation and Geriatrics, Geneva Medical School and University Hospitals,
Chemin Pont Bochet, 3 Thonex-Geneve, CH 1226, Switzerland.
E-mail: Jean-Pierre.Michel@hcuge.ch
Received March 9, 2009; accepted in revised form April 26, 2009.
Coalition of advocates to vaccinate of Western
European citizens aged 60 years and older
Aging Clinical and Experimental Research
Jean-Pierre Michel1, Christian Chidiac2, Beatrix Grubeck-Loebenstein3, Robert W. Johnson4,
Paul Henri Lambert5, Stefania Maggi6, Robert Moulias7, Karl Nicholson8 and Hans Werner9
1Department of Rehabilitation and Geriatrics, Geneva Medical School and University Hospitals,
Thonex-Geneve, Switzerland, 2Service des Maladies Infectieuses et Tropicales, Hôpital de la Croix-Rousse,
Inserm U851, Lyon, France, 3Institute for Biomedical Aging Research, Innsbruck, Austria, 4Bristol Royal
Infirmary and University of Bristol, Bristol, United Kingdom, 5CMU, Centre of Vaccinology, Geneva,
Switzerland, 6CNR, Center on Aging, Padova, Italy, 7Service de Médecine Interne, Hôpital Charles-Foix,
Ivry-sur-Seine, France, 8University Hospitals of Leicester NHS Trust, Leicester Royal Infirmary, Leicester,
United Kingdom, 9Ev. Krankenhaus Elisabethenstift, Darmstadt, Germany
ABSTRACT. The high burden of infectious diseases in
adults aged 60 years and older is disproportionate, con-
sidering that many of these diseases are vaccine-pre-
ventable. Based on careful analysis of the reasons for vac-
cination barriers/failures in the European population,
the two European geriatric and gerontological societies
(the European Union Geriatric Medicine Society [EUGMS]
and the International Association of Gerontology and Geri-
atrics – European Region [IAGG-ER]) propose careful adap-
tation of current vaccine guidelines to promote preventive
aspects, concerning both life threatening-diseases (in-
fluenza, pneumococcal pneumonia and tetanus/diphtheria)
and diseases which adversely impact patients’ quality of
life (pertussis and herpes zoster). This consensus statement
is designed to support official recommendations and im-
prove the willingness to vaccinate the most rapidly grow-
ing segment of the population. The following guidelines
are based on the importance of the sustainability of vac-
cine programs from midlife till extreme old age:
- Promote healthy aging by optimizing health deter-
minants of daily functions, active participation in
society and individual quality of life;
- Provide useful information to contribute toward har-
monizing vaccine strategies at European level;
- Support the public health, social and economic values
of vaccination.
Both healthcare professionals and consumers associa-
tions have a critical role to play in the implementation
of such consensus clinical guidelines.
(Aging Clin Exp Res 2009; 21: 254-257)
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The European geriatric and gerontological societies [Eu-
ropean Union Geriatric Medicine Society (EUGMS)
and International Association of Gerontology and
Geriatrics – European Region (IAGG-ER)], concerned
with the public health burden of vaccine-preventable dis-
eases, convened a Working Group of experts, chaired by
the academic director of the EUGMS (JPM) for the pur-
pose of advocating higher immunization rates among
European citizens aged 60 years and older.
The main purposes of the Joint Working Group were:
1) to conduct an inventory of the current practical guide-
lines for universally recommended vaccines in adults in Eu-
ropean countries, and to compare guidelines with those
of the USA; 2) to propose an adaptation of current vac-
cine guidelines designed to support official recommen-
dations; 3) to stress the importance of sustaining a life-
course vaccine program from childhood to adulthood
until extreme old age; 4) to support the public health, so-
cial and economic value of vaccines to prevent infec-
tious diseases in the whole population; and 5) to en-
hance the willingness to vaccinate and the public accep-
tance of vaccination.
The group was composed of geriatricians designated by
the two societies (EUGMS: SM and JPM and IAGG-ER:
RM and HW) and experts in immunology and vaccines (B-
GL and PHL), pneumococcal vaccine (CC) and influenza
vaccine (KN) and public health (Theri Kilpi), who all
worked on a voluntary basis.
Each of the working member was in charge of a spe-
cific topic (formulating the bibliography, reporting at
each of the three meetings, and participating in the writ-
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ing of the paper related to their main expertise). The aca-
demic director of the EUGMS assured the coordination of
the various chapters and wrote the first draft. All group
members participated in its improvement and agreed
with the content of the final version. The draft state-
ment was then submitted to the executive boards of the
two societies.
Vaccines should be part of a healthy aging strategy, con-
sidering that currently the period from retirement age
(from 55 to 65 years in most Western European countries)
to death is generally two to three decades. Several clinical
considerations must be included in it (Table 1):
- Vaccinations: After a complete vaccine history as-
sessment at 60 years of age, recommended vaccines
include TdaP, influenza, pneumococcal and herpes
zoster. The association of influenza and pneumococ-
cal vaccines has potential preventive effects (1).
Choice of TdaP, a tetanus toxoid, reduced diphtheria
toxoid and acellular pertussis vaccine follows the rec-
ommendation of the US Advisory Committee on Im-
munization Practices (ACIP) (2). Moreover, this com-
bined vaccine reduces the reservoir of pertussis in
the population at large, decreases exposure of persons
at increased risk of complicated infections (e.g., in-
fants) and also reduces the cost and disruption of
pertussis in health care facilities and other institu-
tional settings (2). These different and/or sequential
vaccine shots more often cause local and transitory re-
actions than systemic ones.
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Vaccine program Recommended vaccines Clinical considerations
Starting at 60 years Tetanus-Diphtheria-Pertussis (TdaP) Assess vaccine status
(but possibly earlier) - If no evidence of any previous vaccination, start a new complete
vaccination series.
- If last booster ≥10 years before, give a booster dose
Trivalent Influenza Vaccine (TIV) Adapted to annual strain
Pneumococcal (PV23) Assess vaccine status: if vaccine administered ≥5 years before, give 1 dose
Herpes Zoster Assess vaccine status:
If no evidence of any previous vaccination, give 1 dose
Revaccinations Influenza (TIV) Every YEAR
Pneumococcal (PV23) Every FIVE YEARS
Tetanus-Diphtheria-Pertussis (TdaP) Every TEN YEARS
Herpes Zoster Not yet determined
Special indications
1. New injury event Tetanus-Toxoid (TT) or - If no evidence of any previous vaccination, start a new complete
Tetanus-Diphtheria toxoids (Td) vaccination series.
or TdaP - If last booster ≥10 years before, give a new booster dose
2. Repeated hospital Pneumococcal Ask vaccine history: if vaccine administered ≥5 years, provide a booster
admissions
3. Nursing home Tetanus-Diphtheria-Pertussis (TdaP) If no evidence of any previous vaccination, start a new complete
admissions vaccination series.
- If last booster ≥10 years before, give a new booster dose
Influenza (TIV) No upper age limit;
Herd immunity is important for both residents of nursing home and
healthcare professionals
Pneumococcal If already vaccinated, a booster is recommended if initial vaccination
was ≥5 years
Herpes Zoster If not already administered, give 1 dose. If already vaccinated, need
for revaccination is not yet known
Contra-indications and precautions for every vaccine: Refer to official vaccine recommendations.
http://www.ecdc.eu.int
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5510a1.htm
http://www.clinicalanswers.nhs.uk/index.cfm?question=643
All the above-mentioned vaccines can be administered in the event of: Mild to moderate local reactions after a previous vaccination, mild acute illness, cur-
rent antimicrobial therapy, persons receiving anticoagulant therapy, recent exposure to an infectious disease and stable neurological disorder.
Administration: Maintain recommended vaccine storage temperature, and sterile injection technique, as well as injection route and site (e.g., persons on
anticoagulant therapy can receive subcutaneous instead of intramuscular injections).
A patient vaccination card is strongly recommended.
Table 1 - Proposed vaccine guidelines for adults aged 60 years and older in Western Europe.
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- Revaccinations: an annual influenza vaccination is need-
ed, as each year’s vaccine is adapted to new seasonal
strains. Repeated annual influenza immunizations broad-
en antigenic protection, if the new strains are closely re-
lated (3). Pneumococcal vaccine is recommended every
5 years and TdaP every 10 years. Further studies are
needed to determine the duration of the protective effect
of a single herpes zoster vaccination and to establish
whether a booster for it is required. Regular booster vac-
cinations throughout life are important to maintain the
ability to respond to recall antigens with aging.
Other special indications for vaccinations should be
considered:
- In case of trauma or a new medical event, a booster (or
a complete vaccination) of tetanus toxoid or TdaP may
be provided if the previous tetanus vaccination was
given over 10 years previously.
- In case of repeated hospitalizations, pneumococcal vac-
cine should be considered, if the last immunization dat-
ed back 5 years.
- At the time of admission to residential care (approxi-
mately 85 years in most Western European countries),
a new clinical assessment of vaccine history is recom-
mended, to ascertain if any vaccine updates are needed.
This assessment needs to consider TdaP, influenza,
pneumococcal and herpes zoster vaccines.
Willingness to vaccinate and public acceptance of
vaccination
These vaccine guidelines for citizens aged 60 years and
older, proposed by the two European geriatric and geron-
tological societies, would be justified if there is evidence
such programs are cost-effective and safe.
Despite existing controversies concerning: a) estimat-
ed influenza-related mortality; b) the effectiveness of in-
fluenza vaccine in older adults; c) possible selection bias-
es in cohort studies (4, 5); and d) the need for country-spe-
cific assessment (6). Most recent analysis studies of in-
fluenza vaccine show a high-impact, cost-effective service
for persons aged over 50 years, and even over 70 years
(7-11). Already in the mid-1990s, a cost-effectiveness anal-
ysis of pneumococcal vaccination for prevention of in-
vasive pneumococcal disease in populations aged over 65
years in 10 Western European countries justified wider use
of the vaccine (12). Most cost-effectiveness analyses of
pertussis vaccination in Europe were performed in Ger-
many and based on a Markov model; the results were
more sensitive in favoring routine vaccination of adults
aged 20 to 64 with TdaP, if the incidence of pertussis in
this age group was greater than 120 per 100,000 pop-
ulation (13, 14).
More research is needed on the cost-effectiveness of all
these vaccines in adults aged 60 years and older. Com-
munity and patient values for preventing herpes zoster and
post-herpetic neuralgia are currently under investigation
to determine the quality-adjusted life-years saved (15-
17). Improving vaccine uptake in this population re-
quires addressing numerous barriers to adult immunization,
which involve both consumers’ beliefs and healthcare
professionals’ practices (18, 19).
Consensus statement
The EUGMS and IAGG-ER have formed a Joint Work-
ing Group to complement existing information, propose
vaccine guidelines, and develop a consensus statement
that advocates immunization in adults aged 60 years
and older. This consensus statement:
- Demonstrates the need to strengthen and harmonize
vaccine strategies at the European level;
- Recognises the importance of sustaining a life-course
vaccine program;
- Promotes healthy aging by increasing vaccine coverage
to limit the burden of vaccine-preventable infectious
diseases;
- Supports the public health, social and economic value of
vaccination, and even
- Improves willingness to vaccinate the most rapidly grow-
ing segment of the general population.
Healthcare professionals have a critical role to play in
the implementation of such consensus vaccine guide-
lines. Communication and awareness of vaccine-pre-
ventable diseases, such as an efficient reminder, recall and
information system as well as improved access to vaccines,
constitute the main pillars for success in establishing a vac-
cine program for European citizens aged 60 years and
older.
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